tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

TRDA Stock Latest News

Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks
RatingsEntrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks
19d ago
TRDA
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial
PremiumCompany Announcements
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial
20d ago
8K
TRDA
Entrada receives authorization from UK MHRA to initiate ELEVATE-44-201
PremiumThe Fly
Entrada receives authorization from UK MHRA to initiate ELEVATE-44-201
20d ago
TRDA
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating
PremiumThe Fly
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating
3M ago
TRDA
Entrada Therapeutics initiated with a Buy at Roth MKM
PremiumThe Fly
Entrada Therapeutics initiated with a Buy at Roth MKM
3M ago
TRDA
Entrada Therapeutics price target raised to $28 from $25 at Oppenheimer
PremiumThe FlyEntrada Therapeutics price target raised to $28 from $25 at Oppenheimer
4M ago
TRDA
Entrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright
Premium
The Fly
Entrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright
4M ago
TRDA
Entrada Therapeutics’ Q3 2024 Financial Highlights
Premium
Company Announcements
Entrada Therapeutics’ Q3 2024 Financial Highlights
4M ago
TRDA
Entrada Therapeutics reports Q3 EPS (35c), consensus (73c)
PremiumThe Fly
Entrada Therapeutics reports Q3 EPS (35c), consensus (73c)
4M ago
TRDA
Is TRDA a Buy, Before Earnings?
PremiumPre-Earnings
Is TRDA a Buy, Before Earnings?
4M ago
TRDA
Entrada Therapeutics presents new data on expanding Duchenne Franchise
PremiumThe Fly
Entrada Therapeutics presents new data on expanding Duchenne Franchise
5M ago
TRDA
Entrada promotes Sethuraman to President of Research, Development
PremiumThe Fly
Entrada promotes Sethuraman to President of Research, Development
5M ago
TRDA
Entrada Therapeutics reports Q2 EPS $1.55, consensus 14c
PremiumThe FlyEntrada Therapeutics reports Q2 EPS $1.55, consensus 14c
6M ago
TRDA
Entrada Therapeutics price target lowered to $18 from $20 at H.C. Wainwright
Premium
The Fly
Entrada Therapeutics price target lowered to $18 from $20 at H.C. Wainwright
8M ago
TRDA
Entrada to sell 3.37M shares at $14.85 in registered direct offering
Premium
The Fly
Entrada to sell 3.37M shares at $14.85 in registered direct offering
8M ago
TRDA
Entrada Therapeutics’ Promising Phase 1 DMD Drug Trial Results
PremiumCompany Announcements
Entrada Therapeutics’ Promising Phase 1 DMD Drug Trial Results
8M ago
8K
TRDA
Entrada Therapeutics reports ‘positive’ data from Phase 1 ENTR-601-44-101 trial
PremiumThe Fly
Entrada Therapeutics reports ‘positive’ data from Phase 1 ENTR-601-44-101 trial
8M ago
TRDA
Two new option listings on May 30th
PremiumThe Fly
Two new option listings on May 30th
9M ago
KSPI
TRDA
Entrada Therapeutics reports Q1 EPS 68c, consensus (59c)
PremiumThe Fly
Entrada Therapeutics reports Q1 EPS 68c, consensus (59c)
10M ago
TRDA
Entrada Therapeutics expects cash to fund requirements through 2Q26
PremiumThe FlyEntrada Therapeutics expects cash to fund requirements through 2Q26
12M ago
TRDA
Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)
Premium
The Fly
Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)
12M ago
TRDA
‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks
Premium
Stock Analysis & Ideas
‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks
1y ago
BFH
COIN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >